The genesis of cancer is a precisely organized process in which normal cells undergo genetic alterations that cause the cells to multiply abnormally, colonize, and metastasize to other organs such as the liver, lungs, colon, and brain. Potential drugs that could modify these carcinogenic pathways are the ones that will be used in clinical trials as anti-cancer drugs. Resveratrol (RES) is a polyphenolic natural antitoxin that has been utilized for the treatment of several diseases, owing to its ability to scavenge free radicals, control the expression and activity of antioxidant enzymes, and have effects on inflammation, cancer, aging, diabetes, and cardioprotection. Although RES has a variety of pharmacological uses and shows promising applications in natural medicine, its unpredictable pharmacokinetics compromise its therapeutic efficacy and prevent its use in clinical settings. RES has been encapsulated into various nanocarriers, such as liposomes, polymeric nanoparticles, lipidic nanocarriers, and inorganic nanoparticles, to address these issues. These nanocarriers can modulate drug release, increase bioavailability, and reach therapeutically relevant plasma concentrations. Studies on resveratrol-rich nano-formulations in various cancer types are compiled in the current article. Studies relating to enhanced drug stability, increased therapeutic potential in terms of pharmacokinetics and pharmacodynamics, and reduced toxicity to cells and tissues are the main topics of this research. To keep the readers informed about the current state of resveratrol nano-formulations from an industrial perspective, some recent and significant patent literature has also been provided. Here, the prospects for nano-formulations are briefly discussed, along with machine learning and pharmacometrics methods for resolving resveratrol’s pharmacokinetic concerns.
癌症的发生是一个高度有序的过程，正常细胞经历基因改变，导致细胞异常增殖、定植并转移至肝脏、肺、结肠和大脑等其他器官。能够改变这些致癌通路的潜在药物，将成为临床试验中使用的抗癌药物。白藜芦醇（RES）是一种多酚类天然抗毒素，因其清除自由基、调控抗氧化酶表达与活性的能力，并对炎症、癌症、衰老、糖尿病及心脏保护具有作用，已被用于多种疾病的治疗。尽管白藜芦醇具有多种药理用途，并在天然药物中显示出广阔的应用前景，但其不可预测的药代动力学特性影响了其治疗效果，阻碍了其在临床中的应用。为解决这些问题，白藜芦醇已被封装到各种纳米载体中，如脂质体、聚合物纳米颗粒、脂质纳米载体和无机纳米颗粒。这些纳米载体可以调节药物释放，提高生物利用度，并达到治疗相关的血浆浓度。本文汇总了富含白藜芦醇的纳米制剂在各种癌症类型中的研究。该研究主要关注增强药物稳定性、提高药代动力学和药效学方面的治疗潜力，以及降低对细胞和组织的毒性。为使读者从工业角度了解白藜芦醇纳米制剂的现状，本文还提供了一些近期重要的专利文献。此处简要讨论了纳米制剂的前景，以及用于解决白藜芦醇药代动力学问题的机器学习和药理学计量方法。
Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews
肿瘤(癌症)患者之家